Target Gene/Pathway Pathway / Gene

  

Search results

No. KEGG GENES KEGG PATHWAY KEGG DRUG DrugBank 指定難病告示番号
1 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
2 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
3 SIGMAR1 2件: Amyotrophic lateral sclerosis, Pathways of neurodegeneration - multiple diseases D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
4 CD52 - D02802 Alemtuzumab 22件: 13, 15, 19, 20, 36, 43, 44, 46, 49, 51, 60, 62, 63, 65, 85, 96, 164, 234, 283, 284, 285, 326
5 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D03068 Belimumab 12件: 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300
6 TNFSF13B 4件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
7 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D00529 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
8 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D01385 Ibudilast 2件: 2, 13
9 CYSLTR1 2件: Calcium signaling pathway, Neuroactive ligand-receptor interaction D08229 Montelukast 8件: 6, 13, 46, 61, 63, 85, 98, 228
10 CA5B 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
11 CA5B 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
12 HRH3 1件: Neuroactive ligand-receptor interaction D08040 Histamine 1件: 13
13 CHRM1 8件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide 3件: 6, 13, 19
14 CHRM1 8件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin 3件: 6, 13, 53
15 CHRM1 8件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin 3件: 6, 13, 53
16 CHRM2 6件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide 3件: 6, 13, 19
17 CHRM2 6件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin 3件: 6, 13, 53
18 CHRM2 6件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Cholinergic synapse, Regulation of actin cytoskeleton D00722 Oxybutynin 3件: 6, 13, 53
19 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide 3件: 6, 13, 19
20 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin 3件: 6, 13, 53
21 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin 3件: 6, 13, 53
22 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01269 Solifenacin 3件: 6, 13, 53
23 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D01699 Darifenacin 2件: 6, 13
24 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D03654 Darifenacin 2件: 6, 13
25 CHRM3 11件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Taste transduction, Regulation of actin cytoskeleton, Insulin secretion, Salivary secretion, Gastric acid secretion, Pancreatic secretion, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D08522 Solifenacin 3件: 6, 13, 53
26 CHRM4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00397 Tropicamide 3件: 6, 13, 19
27 CHRM4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00465 Oxybutynin 3件: 6, 13, 53
28 CHRM4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton D00722 Oxybutynin 3件: 6, 13, 53
29 CHRM5 6件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00397 Tropicamide 3件: 6, 13, 19
30 CHRM5 6件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00465 Oxybutynin 3件: 6, 13, 53
31 CHRM5 6件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Regulation of actin cytoskeleton, Alzheimer disease, Pathways of neurodegeneration - multiple diseases D00722 Oxybutynin 3件: 6, 13, 53
32 CHRNA1 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
33 CHRNA1 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
34 CHRNA1 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
35 CHRNA2 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
36 CHRNA2 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
37 CHRNA2 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
38 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
39 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
40 CHRNA3 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
41 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
42 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
43 CHRNA4 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
44 CHRNA5 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
45 CHRNA5 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
46 CHRNA5 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
47 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
48 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
49 CHRNA7 7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Cholinergic synapse, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
50 CHRNB1 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
51 CHRNB1 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
52 CHRNB1 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
53 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
54 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
55 CHRNB2 4件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
56 CHRNB3 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
57 CHRNB3 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
58 CHRNB3 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
59 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
60 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
61 CHRNB4 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
62 CHRND 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
63 CHRND 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
64 CHRND 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
65 CHRNE 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
66 CHRNE 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
67 CHRNE 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
68 CHRNG 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
69 CHRNG 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
70 CHRNG 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
71 CLCN2 1件: Mineral absorption D04790 Lubiprostone 3件: 13, 290, 299
72 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D00306 Dronabinol 8件: 2, 8, 13, 36, 46, 96, 271, 298
73 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D05099 Nabilone 2件: 6, 13
74 CNR1 4件: Rap1 signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Retrograde endocannabinoid signaling D10915 Cannabidiol 19件: 2, 6, 8, 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
75 CNR2 1件: Neuroactive ligand-receptor interaction D00306 Dronabinol 6件: 13, 36, 46, 96, 271, 298
76 CNR2 1件: Neuroactive ligand-receptor interaction D05099 Nabilone 1件: 13
77 CNR2 1件: Neuroactive ligand-receptor interaction D10915 Cannabidiol 16件: 13, 36, 46, 95, 96, 97, 140, 144, 145, 156, 157, 158, 193, 206, 226, 271
78 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00045 Adenosine 3件: 13, 58, 65
79 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
80 ADORA1 7件: cGMP-PKG signaling pathway, cAMP signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
81 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00045 Adenosine 3件: 13, 58, 65
82 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
83 ADORA2A 7件: Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Parkinson disease, Alcoholism D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
84 ADORA2B 5件: Rap1 signaling pathway, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Alcoholism D00045 Adenosine 3件: 13, 58, 65
85 ADORA3 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00045 Adenosine 3件: 13, 58, 65
86 CSF3R 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03235 Filgrastim 34件: 2, 6, 11, 13, 16, 25, 26, 28, 34, 35, 36, 38, 40, 41, 42, 45, 46, 47, 49, 51, 57, 60, 62, 65, 85, 96, 113, 164, 256, 283, 284, 285, 296, 331
87 CSF3R 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03247 Lenograstim 7件: 2, 13, 16, 18, 19, 57, 65
88 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01692 Alfuzosin 1件: 13
89 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D01965 Silodosin 2件: 6, 13
90 ADRA1A 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Salivary secretion D07124 Alfuzosin 1件: 13
91 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine 1件: 13
92 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine 2件: 13, 90
93 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
94 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
95 ADRA2A 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
96 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine 1件: 13
97 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine 2件: 13, 90
98 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
99 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
100 ADRA2B 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
101 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D00776 Tizanidine 1件: 13
102 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D02076 Brimonidine 2件: 13, 90
103 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D04375 Guanabenz 2件: 2, 13
104 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D07540 Brimonidine 2件: 13, 90
105 ADRA2C 2件: cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction D08611 Tizanidine 1件: 13
106 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D02147 Salbutamol 14件: 3, 11, 12, 13, 49, 85, 86, 89, 111, 113, 228, 231, 256, 299
107 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D07713 Clenbuterol 5件: 1, 2, 6, 13, 256
108 ADRB2 9件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Adrenergic signaling in cardiomyocytes, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D08092 Isoxsuprine 1件: 13
109 ADRB3 8件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Thermogenesis, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Chemical carcinogenesis - receptor activation D09535 Mirabegron 4件: 6, 13, 53, 226
110 CYP17A1 6件: Steroid hormone biosynthesis, Metabolic pathways, Ovarian steroidogenesis, Prolactin signaling pathway, Cortisol synthesis and secretion, Cushing syndrome D00351 Ketoconazole 3件: 8, 13, 75
111 DDC 9件: Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Cocaine addiction, Amphetamine addiction, Alcoholism D00558 Carbidopa 9件: 2, 4, 6, 13, 17, 90, 140, 164, 201
112 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
113 DHFR 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
114 DHODH 3件: Pyrimidine metabolism, Metabolic pathways, Biosynthesis of cofactors D10172 Teriflunomide 3件: 13, 25, 26
115 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D00564 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
116 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D01280 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
117 NQO1 7件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D08682 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
118 DNMT1 3件: Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer D03665 Decitabine 3件: 13, 60, 63
119 DNMT3A 3件: Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer D03665 Decitabine 3件: 13, 60, 63
120 DNMT3B 3件: Cysteine and methionine metabolism, Metabolic pathways, MicroRNAs in cancer D03665 Decitabine 3件: 13, 60, 63
121 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D00458 Quetiapine 2件: 6, 13
122 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D01745 Domperidone 5件: 6, 13, 17, 51, 230
123 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D07868 Domperidone 5件: 6, 13, 17, 51, 230
124 DRD2 8件: Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Alcoholism D08456 Quetiapine 2件: 6, 13
125 ABAT 7件: Alanine, aspartate and glutamate metabolism, Valine, leucine and isoleucine degradation, beta-Alanine metabolism, Propanoate metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
126 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10001 Fingolimod 3件: 13, 14, 156
127 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
128 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11215 Ponesimod 1件: 13
129 S1PR1 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod 2件: 13, 50
130 S1PR3 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
131 EDNRA 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D01227 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
132 EDNRA 7件: Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Renin secretion, Pathways in cancer D07538 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
133 EDNRB 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D01227 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
134 EDNRB 6件: Calcium signaling pathway, cGMP-PKG signaling pathway, Neuroactive ligand-receptor interaction, Melanogenesis, Relaxin signaling pathway, Pathways in cancer D07538 Bosentan 11件: 13, 41, 47, 51, 84, 85, 86, 88, 210, 211, 212
135 ELANE 3件: Neutrophil extracellular trap formation, Transcriptional misregulation in cancer, Systemic lupus erythematosus D03788 Sivelestat 3件: 13, 85, 96
136 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D00142 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
137 DHFR2 5件: One carbon pool by folate, Folate biosynthesis, Metabolic pathways, Biosynthesis of cofactors, Antifolate resistance D02115 Methotrexate 38件: 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331
138 EPOR 5件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Pathways in cancer D03231 Erythropoietin 10件: 2, 6, 13, 18, 22, 46, 47, 70, 95, 96
139 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
140 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00185 Estriol 2件: 13, 227
141 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00554 Ethinylestradiol 4件: 13, 46, 49, 299
142 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01413 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
143 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01617 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
144 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01953 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
145 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01986 Estriol 2件: 13, 227
146 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04061 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
147 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04063 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
148 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04064 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
149 ESR1 9件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, Thyroid hormone signaling pathway, Endocrine and other factor-regulated calcium reabsorption, Pathways in cancer, Proteoglycans in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04065 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
150 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00105 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
151 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D00185 Estriol 2件: 13, 227
152 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01413 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
153 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01617 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
154 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01953 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
155 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D01986 Estriol 2件: 13, 227
156 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04061 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
157 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04063 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
158 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04064 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
159 ESR2 7件: Endocrine resistance, Estrogen signaling pathway, Prolactin signaling pathway, GnRH secretion, Pathways in cancer, Chemical carcinogenesis - receptor activation, Breast cancer D04065 Estradiol 7件: 13, 46, 49, 65, 76, 226, 299
160 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D01968 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
161 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06378 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
162 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D06379 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
163 FDPS 4件: Terpenoid backbone biosynthesis, Metabolic pathways, Influenza A, Human T-cell leukemia virus 1 infection D08689 Zoledronic acid 13件: 5, 6, 13, 17, 46, 65, 93, 95, 96, 270, 274, 299, 333
164 FGFR2 13件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Signaling pathways regulating pluripotency of stem cells, Regulation of actin cytoskeleton, Pathways in cancer, Prostate cancer, Gastric cancer, Central carbon metabolism in cancer D05338 Palifermin 5件: 13, 36, 38, 39, 65
165 NCSTN 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
166 CA14 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
167 CA14 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
168 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D00753 Sirolimus 41件: 2, 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 96, 98, 127, 137, 157, 158, 192, 193, 222, 256, 277, 278, 279, 280, 281, 283, 285, 331
169 MTOR 51件: EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, HIF-1 signaling pathway, Phospholipase D signaling pathway, Autophagy - other, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Cellular senescence, Apelin signaling pathway, Neutrophil extracellular trap formation, JAK-STAT signaling pathway, Th17 cell differentiation, Thermogenesis, Insulin signaling pathway, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Growth hormone synthesis, secretion and action, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Shigellosis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Human immunodeficiency virus 1 infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Colorectal cancer, Pancreatic cancer, Glioma, Prostate cancer, Acute myeloid leukemia, Breast cancer, Hepatocellular carcinoma, Gastric cancer, Central carbon metabolism in cancer, Choline metabolism in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, Diabetic cardiomyopathy D06068 Temsirolimus 4件: 13, 34, 89, 331
170 GABBR1 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen 7件: 2, 10, 13, 18, 65, 149, 206
171 GABBR1 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D08861 Arbaclofen Placarbil 1件: 13
172 GABBR1 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D09791 Arbaclofen 2件: 13, 206
173 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
174 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
175 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
176 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
177 GABRA1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
178 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
179 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
180 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
181 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
182 GABRA2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
183 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
184 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
185 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
186 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
187 GABRA3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
188 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
189 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
190 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
191 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
192 GABRA4 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
193 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
194 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
195 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
196 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
197 GABRA5 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
198 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
199 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
200 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
201 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
202 GABRA6 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Taste transduction, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
203 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
204 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
205 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
206 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
207 GABRB1 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
208 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
209 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
210 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
211 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
212 GABRB2 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
213 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
214 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
215 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
216 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
217 GABRB3 6件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, Serotonergic synapse, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
218 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
219 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
220 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
221 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
222 GABRD 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
223 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
224 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
225 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
226 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
227 GABRE 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
228 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
229 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
230 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
231 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
232 GABRG1 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
233 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
234 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
235 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
236 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
237 GABRG2 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
238 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
239 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
240 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
241 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
242 GABRG3 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
243 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
244 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
245 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
246 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
247 GABRP 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
248 GAD1 7件: Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
249 GAD2 7件: Alanine, aspartate and glutamate metabolism, beta-Alanine metabolism, Taurine and hypotaurine metabolism, Butanoate metabolism, Metabolic pathways, GABAergic synapse, Type I diabetes mellitus D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
250 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
251 ABL1 11件: ErbB signaling pathway, Ras signaling pathway, Cell cycle, Axon guidance, Neurotrophin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, MicroRNAs in cancer, Chemical carcinogenesis - reactive oxygen species, Chronic myeloid leukemia, Viral myocarditis D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
252 GHR 5件: Cytokine-cytokine receptor interaction, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Growth hormone synthesis, secretion and action D02691 Somatotropin 23件: 2, 3, 13, 19, 46, 65, 74, 75, 76, 78, 96, 107, 113, 187, 191, 193, 195, 236, 238, 265, 274, 276, 299
253 GHRHR 2件: Neuroactive ligand-receptor interaction, Growth hormone synthesis, secretion and action D08523 Somatorelin 2件: 13, 78
254 GLP1R 3件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Insulin secretion D09889 Dulaglutide 2件: 13, 299
255 GRIA1 14件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
256 GRIA2 15件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
257 GRIA3 13件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Long-term depression, Huntington disease, Spinocerebellar ataxia, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction, Transcriptional misregulation in cancer D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
258 GRIA4 10件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Dopaminergic synapse, Huntington disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Nicotine addiction D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
259 GRIK1 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
260 GRIK2 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
261 GRIK3 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
262 GRIK4 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
263 GRIK5 2件: Neuroactive ligand-receptor interaction, Glutamatergic synapse D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
264 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
265 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
266 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00777 Amantadine 4件: 6, 8, 13, 127
267 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
268 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
269 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
270 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
271 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine 4件: 6, 8, 13, 127
272 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
273 GRIN1 18件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
274 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
275 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
276 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00777 Amantadine 4件: 6, 8, 13, 127
277 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
278 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
279 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
280 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
281 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine 4件: 6, 8, 13, 127
282 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
283 GRIN2A 19件: Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
284 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
285 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
286 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00777 Amantadine 4件: 6, 8, 13, 127
287 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
288 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
289 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
290 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
291 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D07441 Amantadine 4件: 6, 8, 13, 127
292 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
293 GRIN2B 19件: Ras signaling pathway, Rap1 signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism, Systemic lupus erythematosus D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
294 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
295 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
296 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00777 Amantadine 4件: 6, 8, 13, 127
297 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
298 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
299 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
300 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
301 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine 4件: 6, 8, 13, 127
302 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
303 GRIN2C 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
304 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00711 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
305 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00775 Riluzole 9件: 2, 3, 5, 8, 13, 17, 18, 203, 206
306 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00777 Amantadine 4件: 6, 8, 13, 127
307 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D00848 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
308 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03742 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
309 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D03744 Dextromethorphan 11件: 2, 6, 8, 13, 21, 46, 78, 85, 96, 97, 156
310 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D04905 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
311 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D07441 Amantadine 4件: 6, 8, 13, 127
312 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08098 Ketamine 8件: 2, 4, 6, 13, 70, 113, 156, 215
313 GRIN2D 15件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Circadian entrainment, Long-term potentiation, Glutamatergic synapse, Alzheimer disease, Amyotrophic lateral sclerosis, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Nicotine addiction, Alcoholism D08174 Memantine 7件: 2, 6, 8, 13, 49, 127, 205
314 NR3C1 1件: Neuroactive ligand-receptor interaction D00292 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
315 NR3C1 1件: Neuroactive ligand-receptor interaction D00407 Methylprednisolone 45件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
316 NR3C1 1件: Neuroactive ligand-receptor interaction D00472 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
317 NR3C1 1件: Neuroactive ligand-receptor interaction D00473 Prednisone 45件: 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331
318 NR3C1 1件: Neuroactive ligand-receptor interaction D00751 Methylprednisolone 45件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
319 NR3C1 1件: Neuroactive ligand-receptor interaction D00975 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
320 NR3C1 1件: Neuroactive ligand-receptor interaction D00979 Methylprednisolone 45件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
321 NR3C1 1件: Neuroactive ligand-receptor interaction D00980 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
322 NR3C1 1件: Neuroactive ligand-receptor interaction D00981 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
323 NR3C1 1件: Neuroactive ligand-receptor interaction D00982 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
324 NR3C1 1件: Neuroactive ligand-receptor interaction D01239 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
325 NR3C1 1件: Neuroactive ligand-receptor interaction D01510 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
326 NR3C1 1件: Neuroactive ligand-receptor interaction D01615 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
327 NR3C1 1件: Neuroactive ligand-receptor interaction D01632 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
328 NR3C1 1件: Neuroactive ligand-receptor interaction D01948 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
329 NR3C1 1件: Neuroactive ligand-receptor interaction D01998 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
330 NR3C1 1件: Neuroactive ligand-receptor interaction D02156 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
331 NR3C1 1件: Neuroactive ligand-receptor interaction D02174 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
332 NR3C1 1件: Neuroactive ligand-receptor interaction D02591 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
333 NR3C1 1件: Neuroactive ligand-receptor interaction D02592 Dexamethasone 25件: 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299
334 NR3C1 1件: Neuroactive ligand-receptor interaction D03301 Prednisolone 41件: 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307
335 NR3C1 1件: Neuroactive ligand-receptor interaction D05000 Methylprednisolone 45件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
336 NR3C1 1件: Neuroactive ligand-receptor interaction D05000 Methylprednisolone hemisuccinate 7件: 13, 49, 50, 51, 53, 97, 211
337 NR3C1 1件: Neuroactive ligand-receptor interaction D05001 Methylprednisolone 45件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
338 NR3C1 1件: Neuroactive ligand-receptor interaction D05002 Methylprednisolone 45件: 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300
339 SERPIND1 1件: Complement and coagulation cascades D08547 Sulodexide 4件: 13, 51, 271, 288
340 HCRTR1 1件: Neuroactive ligand-receptor interaction D10082 Suvorexant 1件: 13
341 HCRTR2 1件: Neuroactive ligand-receptor interaction D10082 Suvorexant 1件: 13
342 HLA-A 19件: Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
343 HLA-B 19件: Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
344 HLA-C 19件: Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
345 HLA-DMA 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
346 HLA-DMB 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
347 HLA-DOA 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
348 HLA-DOB 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
349 HLA-DPA1 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
350 HLA-DPB1 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
351 HLA-DQA1 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
352 HLA-DQA2 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
353 HLA-DQB1 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
354 HLA-DRA 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
355 HLA-DRB1 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
356 HLA-DRB3 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
357 HLA-DRB4 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
358 HLA-DRB5 24件: Phagosome, Cell adhesion molecules, Antigen processing and presentation, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Intestinal immune network for IgA production, Type I diabetes mellitus, Leishmaniasis, Toxoplasmosis, Staphylococcus aureus infection, Tuberculosis, Influenza A, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
359 HLA-E 19件: Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
360 HLA-F 18件: Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
361 HLA-G 19件: Endocytosis, Phagosome, Cellular senescence, Cell adhesion molecules, Antigen processing and presentation, Natural killer cell mediated cytotoxicity, Type I diabetes mellitus, Human cytomegalovirus infection, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Viral carcinogenesis, Autoimmune thyroid disease, Allograft rejection, Graft-versus-host disease, Viral myocarditis D04318 Glatiramer 4件: 2, 13, 96, 156
362 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00434 Simvastatin 21件: 6, 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310
363 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00887 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
364 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D00893 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
365 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D07474 Atorvastatin 18件: 13, 46, 49, 51, 58, 63, 79, 84, 88, 93, 96, 97, 160, 222, 225, 265, 271, 299
366 HMGCR 4件: Terpenoid backbone biosynthesis, Metabolic pathways, AMPK signaling pathway, Bile secretion D08410 Pravastatin 9件: 13, 46, 49, 67, 79, 96, 164, 265, 333
367 HPRT1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D06109 Tioguanine 2件: 13, 37
368 HPRT1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D08603 Tioguanine 2件: 13, 37
369 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00300 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
370 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00364 Loratadine 4件: 13, 46, 89, 98
371 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00664 Cetirizine 4件: 13, 28, 35, 300
372 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00666 Clemastine 1件: 13
373 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00669 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
374 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D00671 Fexofenadine 2件: 13, 46
375 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D02419 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
376 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03285 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
377 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03360 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
378 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03535 Clemastine 1件: 13
379 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03693 Desloratadine 1件: 13
380 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D03854 Diphenhydramine 10件: 11, 13, 49, 51, 70, 86, 96, 222, 256, 300
381 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07662 Cetirizine 4件: 13, 28, 35, 300
382 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07803 Dexchlorpheniramine 2件: 13, 49
383 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D07958 Fexofenadine 2件: 13, 46
384 HRH1 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Inflammatory mediator regulation of TRP channels D08040 Histamine 1件: 13
385 HRH2 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00422 Ranitidine 2件: 13, 65
386 HRH2 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D00673 Ranitidine 2件: 13, 65
387 HRH2 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gastric acid secretion D08040 Histamine 1件: 13
388 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00274 Cisapride 1件: 13
389 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D00458 Quetiapine 2件: 6, 13
390 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D02092 Cisapride 1件: 13
391 HTR2A 5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Gap junction, Serotonergic synapse, Inflammatory mediator regulation of TRP channels D08456 Quetiapine 2件: 6, 13
392 HTR3A 2件: Serotonergic synapse, Taste transduction D00274 Cisapride 1件: 13
393 HTR3A 2件: Serotonergic synapse, Taste transduction D02092 Cisapride 1件: 13
394 HTR4 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D00274 Cisapride 1件: 13
395 HTR4 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D02092 Cisapride 1件: 13
396 HTR4 4件: Calcium signaling pathway, cAMP signaling pathway, Neuroactive ligand-receptor interaction, Serotonergic synapse D09205 Prucalopride 3件: 13, 51, 96
397 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D00746 Interferon beta-1b 1件: 13
398 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
399 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
400 IFNAR1 18件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Hepatitis B, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
401 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D00746 Interferon beta-1b 1件: 13
402 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D03305 Interferon alfa 6件: 13, 25, 26, 28, 56, 96
403 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D04554 Interferon beta-1a 4件: 13, 26, 96, 97
404 IFNAR2 17件: Cytokine-cytokine receptor interaction, PI3K-Akt signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, JAK-STAT signaling pathway, Natural killer cell mediated cytotoxicity, Hepatitis C, Measles, Influenza A, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer D10483 Peginterferon beta-1a 1件: 13
405 IL1A 21件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, Necroptosis, Cellular senescence, Osteoclast differentiation, Hematopoietic cell lineage, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pertussis, Leishmaniasis, Tuberculosis, Measles, Influenza A, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
406 IL1B 44件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Necroptosis, Osteoclast differentiation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Inflammatory mediator regulation of TRP channels, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Measles, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
407 IL1R1 13件: MAPK signaling pathway, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Hematopoietic cell lineage, Th17 cell differentiation, Inflammatory mediator regulation of TRP channels, Pathogenic Escherichia coli infection, Shigellosis, Amoebiasis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
408 IL2RA 11件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Endocytosis, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th1 and Th2 cell differentiation, Th17 cell differentiation, Measles, Human T-cell leukemia virus 1 infection, Pathways in cancer D03639 Daclizumab 8件: 13, 56, 60, 65, 97, 107, 283, 284
409 IL6 51件: EGFR tyrosine kinase inhibitor resistance, Antifolate resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, Cellular senescence, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, Cytosolic DNA-sensing pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Th17 cell differentiation, TNF signaling pathway, Intestinal immune network for IgA production, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Chagas disease, African trypanosomiasis, Malaria, Amoebiasis, Tuberculosis, Hepatitis B, Measles, Human cytomegalovirus infection, Influenza A, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Coronavirus disease - COVID-19, Pathways in cancer, Transcriptional misregulation in cancer, Inflammatory bowel disease, Rheumatoid arthritis, Graft-versus-host disease, Hypertrophic cardiomyopathy, Lipid and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
410 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D02596 Tocilizumab 21件: 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331
411 IL6R 12件: EGFR tyrosine kinase inhibitor resistance, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, HIF-1 signaling pathway, PI3K-Akt signaling pathway, JAK-STAT signaling pathway, Hematopoietic cell lineage, Th17 cell differentiation, Non-alcoholic fatty liver disease, Human cytomegalovirus infection, Coronavirus disease - COVID-19, Pathways in cancer D11079 Satralizumab 2件: 11, 13
412 IL10 22件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, FoxO signaling pathway, C-type lectin receptor signaling pathway, JAK-STAT signaling pathway, T cell receptor signaling pathway, Intestinal immune network for IgA production, Pertussis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Staphylococcus aureus infection, Tuberculosis, Asthma, Autoimmune thyroid disease, Inflammatory bowel disease, Systemic lupus erythematosus, Allograft rejection D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
413 IL17A 6件: Cytokine-cytokine receptor interaction, IL-17 signaling pathway, Th17 cell differentiation, Alcoholic liver disease, Inflammatory bowel disease, Rheumatoid arthritis D09967 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271
414 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D00752 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
415 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05094 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
416 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05095 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
417 IMPDH1 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid 36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
418 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D00752 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
419 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05094 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
420 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05095 Mycophenolate mofetil 34件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300
421 IMPDH2 3件: Purine metabolism, Drug metabolism - other enzymes, Metabolic pathways D05096 Mycophenolic acid 36件: 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300
422 ITGA4 14件: PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D06590 Firategrast 1件: 13
423 ITGA4 14件: PI3K-Akt signaling pathway, Focal adhesion, ECM-receptor interaction, Cell adhesion molecules, Hematopoietic cell lineage, Leukocyte transendothelial migration, Intestinal immune network for IgA production, Regulation of actin cytoskeleton, Yersinia infection, Leishmaniasis, Human papillomavirus infection, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D06886 Natalizumab 6件: 13, 15, 25, 46, 63, 96
424 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00075 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
425 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00957 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
426 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
427 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00958 Testosterone enanthate 2件: 13, 113
428 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D00959 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
429 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06085 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
430 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone 9件: 1, 2, 3, 13, 60, 76, 78, 113, 265
431 AR 4件: Oocyte meiosis, Pathways in cancer, Chemical carcinogenesis - receptor activation, Prostate cancer D06087 Testosterone undecanoate 2件: 13, 60
432 ITGAL 12件: Rap1 signaling pathway, Cell adhesion molecules, Neutrophil extracellular trap formation, Natural killer cell mediated cytotoxicity, Leukocyte transendothelial migration, Regulation of actin cytoskeleton, Malaria, Staphylococcus aureus infection, Human T-cell leukemia virus 1 infection, Epstein-Barr virus infection, Rheumatoid arthritis, Viral myocarditis D03959 Efalizumab 9件: 11, 13, 37, 46, 49, 53, 61, 95, 96
433 KCNA4 2件: Cortisol synthesis and secretion, Cushing syndrome D04127 Dalfampridine 5件: 3, 4, 6, 13, 14
434 KCNC3 1件: Spinocerebellar ataxia D04127 Dalfampridine 2件: 13, 14
435 KCND2 1件: Serotonergic synapse D04127 Dalfampridine 2件: 13, 14
436 KCND3 1件: Spinocerebellar ataxia D04127 Dalfampridine 2件: 13, 14
437 KCNJ11 3件: Insulin secretion, GnRH secretion, Type II diabetes mellitus D00294 Diazoxide 2件: 13, 193
438 CA13 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
439 CA13 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
440 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
441 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
442 KIT 11件: MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Phospholipase D signaling pathway, PI3K-Akt signaling pathway, Hematopoietic cell lineage, Melanogenesis, Pathways in cancer, Acute myeloid leukemia, Breast cancer, Central carbon metabolism in cancer D10229 Masitinib 6件: 2, 5, 6, 13, 46, 96
443 LTB 3件: Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis D08866 Baminercept 4件: 13, 46, 53, 97
444 MAOB 14件: Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D02562 Rasagiline 7件: 2, 5, 6, 13, 17, 58, 66
445 MAOB 14件: Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D08469 Rasagiline 7件: 2, 5, 6, 13, 17, 58, 66
446 MAOB 14件: Glycine, serine and threonine metabolism, Arginine and proline metabolism, Histidine metabolism, Tyrosine metabolism, Phenylalanine metabolism, Tryptophan metabolism, Drug metabolism - cytochrome P450, Metabolic pathways, Serotonergic synapse, Dopaminergic synapse, Parkinson disease, Cocaine addiction, Amphetamine addiction, Alcoholism D10829 Rasagiline 7件: 2, 5, 6, 13, 17, 58, 66
447 MC2R 5件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome D00146 Corticotropin 15件: 2, 13, 14, 46, 49, 50, 66, 75, 78, 81, 84, 145, 193, 205, 222
448 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D00670 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
449 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D02558 Rivastigmine 3件: 5, 6, 13
450 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D03822 Rivastigmine 3件: 5, 6, 13
451 ACHE 2件: Glycerophospholipid metabolism, Cholinergic synapse D07869 Donepezil 9件: 5, 6, 13, 46, 78, 124, 127, 156, 206
452 MTNR1A 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
453 MTNR1B 2件: Neuroactive ligand-receptor interaction, Circadian entrainment D08170 Melatonin 12件: 6, 8, 13, 37, 46, 49, 90, 97, 144, 145, 149, 202
454 SERPINC1 1件: Complement and coagulation cascades D08547 Sulodexide 4件: 13, 51, 271, 288
455 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
456 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
457 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
458 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D02593 Pantoprazole 2件: 13, 65
459 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
460 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
461 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
462 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole 2件: 13, 65
463 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
464 ATP4A 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
465 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D00455 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
466 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01207 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
467 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D01984 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
468 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D02593 Pantoprazole 2件: 13, 65
469 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D04056 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
470 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05259 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
471 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05261 Omeprazole 16件: 6, 8, 13, 21, 46, 51, 85, 96, 97, 98, 225, 271, 282, 294, 298, 299
472 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D05353 Pantoprazole 2件: 13, 65
473 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D07917 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
474 ATP4B 4件: Oxidative phosphorylation, Metabolic pathways, Collecting duct acid secretion, Gastric acid secretion D09339 Esomeprazole 8件: 13, 46, 86, 98, 107, 113, 298, 299
475 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D00729 Loperamide 2件: 13, 97
476 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
477 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
478 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
479 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
480 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
481 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D07113 Loperamide 2件: 13, 97
482 OPRD1 3件: cGMP-PKG signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D08144 Loperamide 2件: 13, 97
483 OPRK1 1件: Neuroactive ligand-receptor interaction D00729 Loperamide 2件: 13, 97
484 OPRK1 1件: Neuroactive ligand-receptor interaction D02095 Naltrexone 11件: 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
485 OPRK1 1件: Neuroactive ligand-receptor interaction D03783 Oxycodone 6件: 13, 46, 70, 226, 231, 298
486 OPRK1 1件: Neuroactive ligand-receptor interaction D05113 Naltrexone 11件: 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
487 OPRK1 1件: Neuroactive ligand-receptor interaction D05312 Oxycodone 6件: 13, 46, 70, 226, 231, 298
488 OPRK1 1件: Neuroactive ligand-receptor interaction D05462 Oxycodone 6件: 13, 46, 70, 226, 231, 298
489 OPRK1 1件: Neuroactive ligand-receptor interaction D07113 Loperamide 2件: 13, 97
490 OPRK1 1件: Neuroactive ligand-receptor interaction D08144 Loperamide 2件: 13, 97
491 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D00729 Loperamide 2件: 13, 97
492 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D02095 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
493 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D03783 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
494 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05113 Naltrexone 13件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 46, 96, 97, 226
495 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05312 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
496 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D05462 Oxycodone 7件: 6, 13, 46, 70, 226, 231, 298
497 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D07113 Loperamide 2件: 13, 97
498 OPRM1 3件: Neuroactive ligand-receptor interaction, Estrogen signaling pathway, Morphine addiction D08144 Loperamide 2件: 13, 97
499 APH1A 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
500 PDCD1 3件: Cell adhesion molecules, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer D10316 Nivolumab 12件: 13, 26, 41, 46, 49, 50, 51, 53, 85, 96, 97, 159
501 PDE2A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
502 PDE2A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, Olfactory transduction, Aldosterone synthesis and secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
503 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
504 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01385 Ibudilast 2件: 2, 13
505 PDE3A 6件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
506 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
507 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01385 Ibudilast 2件: 2, 13
508 PDE3B 11件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
509 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
510 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
511 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
512 PDE4A 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
513 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
514 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
515 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
516 PDE4B 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
517 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
518 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
519 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
520 PDE4C 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
521 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
522 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01385 Ibudilast 2件: 2, 13
523 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
524 PDE4D 5件: Purine metabolism, Metabolic pathways, cAMP signaling pathway, Parathyroid hormone synthesis, secretion and action, Morphine addiction D01783 Rolipram 2件: 8, 13
525 PDE1B 7件: Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
526 PDE1B 7件: Purine metabolism, Metabolic pathways, Calcium signaling pathway, Olfactory transduction, Taste transduction, Renin secretion, Morphine addiction D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
527 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D01441 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
528 PDGFRA 20件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, Phospholipase D signaling pathway, Endocytosis, PI3K-Akt signaling pathway, Focal adhesion, Gap junction, JAK-STAT signaling pathway, Regulation of actin cytoskeleton, Human cytomegalovirus infection, Pathways in cancer, MicroRNAs in cancer, Glioma, Prostate cancer, Melanoma, Central carbon metabolism in cancer, Choline metabolism in cancer D08066 Imatinib 12件: 13, 28, 34, 35, 46, 51, 85, 86, 87, 88, 89, 162
529 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00182 Norethisterone 4件: 13, 46, 49, 299
530 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00950 Levonorgestrel 1件: 13
531 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00951 Medroxyprogesterone acetate 6件: 13, 35, 46, 49, 51, 60
532 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D00953 Norethisterone 4件: 13, 46, 49, 299
533 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D01217 Dydrogesterone 1件: 13
534 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D07222 Nomegestrol 1件: 13
535 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D08166 Medroxyprogesterone acetate 6件: 13, 35, 46, 49, 51, 60
536 PGR 5件: Oocyte meiosis, Progesterone-mediated oocyte maturation, Estrogen signaling pathway, Chemical carcinogenesis - receptor activation, Breast cancer D08281 Nomegestrol acetate 1件: 13
537 S1PR5 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
538 S1PR5 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D11460 Siponimod 2件: 13, 50
539 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D00945 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
540 PPARG 11件: PPAR signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Osteoclast differentiation, Thermogenesis, Non-alcoholic fatty liver disease, Huntington disease, Pathways in cancer, Transcriptional misregulation in cancer, Thyroid cancer, Lipid and atherosclerosis D08378 Pioglitazone 17件: 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299
541 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
542 PPP3CA 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
543 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
544 PPP3CB 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
545 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
546 PPP3CC 33件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Dopaminergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
547 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
548 PPP3R1 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
549 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D00107 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
550 PPP3R2 32件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, Oocyte meiosis, Cellular senescence, Wnt signaling pathway, Axon guidance, VEGF signaling pathway, Osteoclast differentiation, C-type lectin receptor signaling pathway, Natural killer cell mediated cytotoxicity, Th1 and Th2 cell differentiation, Th17 cell differentiation, T cell receptor signaling pathway, B cell receptor signaling pathway, Long-term potentiation, Glutamatergic synapse, Oxytocin signaling pathway, Glucagon signaling pathway, Renin secretion, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Tuberculosis, Human cytomegalovirus infection, Human T-cell leukemia virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Human immunodeficiency virus 1 infection, PD-L1 expression and PD-1 checkpoint pathway in cancer, Lipid and atherosclerosis D08556 Tacrolimus 34件: 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299
551 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D03365 Nicotine 3件: 6, 13, 84
552 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05156 Nicotine 3件: 6, 13, 84
553 CHRNA9 2件: Neuroactive ligand-receptor interaction, Chemical carcinogenesis - receptor activation D05157 Nicotine 3件: 6, 13, 84
554 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
555 PRKAA1 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
556 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D00944 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
557 PRKAA2 20件: FoxO signaling pathway, Autophagy - animal, mTOR signaling pathway, PI3K-Akt signaling pathway, AMPK signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Apelin signaling pathway, Tight junction, Circadian rhythm, Thermogenesis, Insulin signaling pathway, Adipocytokine signaling pathway, Oxytocin signaling pathway, Glucagon signaling pathway, Insulin resistance, Non-alcoholic fatty liver disease, Alcoholic liver disease, Hypertrophic cardiomyopathy, Fluid shear stress and atherosclerosis D04966 Metformin 24件: 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301
558 CACNA2D3 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
559 CACNA2D3 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
560 PSENEN 2件: Notch signaling pathway, Alzheimer disease D09010 Tarenflurbil 1件: 13
561 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00550 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
562 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00696 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
563 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D00697 Flumazenil 5件: 6, 13, 17, 18, 206
564 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D02624 Eszopiclone 3件: 6, 13, 46
565 GABRQ 5件: Neuroactive ligand-receptor interaction, Retrograde endocannabinoid signaling, GABAergic synapse, Morphine addiction, Nicotine addiction D05028 Midazolam 12件: 2, 3, 6, 13, 21, 46, 70, 96, 97, 231, 272, 298
566 PSEN1 6件: Wnt signaling pathway, Notch signaling pathway, Neurotrophin signaling pathway, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Human papillomavirus infection D09010 Tarenflurbil 1件: 13
567 PSMB5 8件: Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D03150 Bortezomib 16件: 11, 13, 26, 28, 46, 49, 51, 61, 63, 64, 66, 228, 256, 283, 288, 331
568 PSMB5 8件: Proteasome, Alzheimer disease, Parkinson disease, Amyotrophic lateral sclerosis, Huntington disease, Spinocerebellar ataxia, Prion disease, Pathways of neurodegeneration - multiple diseases D10130 Ixazomib 5件: 13, 16, 28, 51, 61
569 RGMA 2件: TGF-beta signaling pathway, Axon guidance D11355 Elezanumab 1件: 13
570 CHRNA10 1件: Neuroactive ligand-receptor interaction D03365 Nicotine 2件: 13, 84
571 CHRNA10 1件: Neuroactive ligand-receptor interaction D05156 Nicotine 2件: 13, 84
572 CHRNA10 1件: Neuroactive ligand-receptor interaction D05157 Nicotine 2件: 13, 84
573 PTGDR 1件: Neuroactive ligand-receptor interaction D01128 Ramatroban 1件: 13
574 PTGIR 3件: Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction, Platelet activation D01385 Ibudilast 2件: 2, 13
575 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00109 Acetylsalicylic acid 15件: 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
576 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00118 Naproxen 4件: 13, 46, 107, 271
577 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
578 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
579 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00330 Flurbiprofen 3件: 13, 21, 46
580 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00903 Diclofenac 5件: 13, 34, 46, 78, 271
581 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D00904 Diclofenac 5件: 13, 34, 46, 78, 271
582 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01122 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
583 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D01475 Flurbiprofen 3件: 13, 21, 46
584 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D02290 Flurbiprofen 3件: 13, 21, 46
585 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D04490 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
586 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D06606 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
587 PTGS1 5件: Arachidonic acid metabolism, Metabolic pathways, Platelet activation, Serotonergic synapse, Regulation of lipolysis in adipocytes D07816 Diclofenac 5件: 13, 34, 46, 78, 271
588 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00109 Acetylsalicylic acid 15件: 13, 22, 34, 46, 49, 51, 58, 86, 96, 97, 113, 158, 210, 231, 251
589 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00118 Naproxen 4件: 13, 46, 107, 271
590 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00126 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
591 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00217 Acetaminophen 18件: 3, 6, 11, 13, 34, 35, 46, 49, 51, 70, 86, 96, 222, 231, 256, 271, 300, 337
592 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00330 Flurbiprofen 3件: 13, 21, 46
593 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00903 Diclofenac 5件: 13, 34, 46, 78, 271
594 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D00904 Diclofenac 5件: 13, 34, 46, 78, 271
595 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01122 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
596 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D01475 Flurbiprofen 3件: 13, 21, 46
597 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D02290 Flurbiprofen 3件: 13, 21, 46
598 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D04490 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
599 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D06606 Ibuprofen 7件: 13, 46, 65, 107, 113, 271, 299
600 PTGS2 22件: Arachidonic acid metabolism, Metabolic pathways, NF-kappa B signaling pathway, VEGF signaling pathway, C-type lectin receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, Retrograde endocannabinoid signaling, Serotonergic synapse, Ovarian steroidogenesis, Oxytocin signaling pathway, Regulation of lipolysis in adipocytes, Alzheimer disease, Pathways of neurodegeneration - multiple diseases, Leishmaniasis, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Chemical carcinogenesis - DNA adducts, MicroRNAs in cancer, Small cell lung cancer D07816 Diclofenac 5件: 13, 34, 46, 78, 271
601 RARA 5件: Th17 cell differentiation, Estrogen signaling pathway, Pathways in cancer, Transcriptional misregulation in cancer, Acute myeloid leukemia D06543 Vitamin A 3件: 13, 53, 90
602 RARB 4件: Pathways in cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer D06543 Vitamin A 3件: 13, 53, 90
603 HRH4 1件: Neuroactive ligand-receptor interaction D08040 Histamine 1件: 13
604 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D01370 Cladribine 3件: 11, 13, 94
605 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D01907 Fludarabine 19件: 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
606 RRM1 5件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways D07966 Fludarabine 19件: 13, 19, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326
607 RRM2 6件: Purine metabolism, Pyrimidine metabolism, Glutathione metabolism, Drug metabolism - other enzymes, Metabolic pathways, p53 signaling pathway D00341 Hydroxyurea 8件: 3, 13, 19, 20, 65, 85, 86, 284
608 RXRA 17件: PPAR signaling pathway, PI3K-Akt signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Non-alcoholic fatty liver disease, Bile secretion, Hepatitis C, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis D03106 Bexarotene 2件: 13, 75
609 RXRB 13件: PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis D03106 Bexarotene 2件: 13, 75
610 RXRG 13件: PPAR signaling pathway, Th17 cell differentiation, Thyroid hormone signaling pathway, Adipocytokine signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Transcriptional misregulation in cancer, Chemical carcinogenesis - receptor activation, Thyroid cancer, Small cell lung cancer, Non-small cell lung cancer, Gastric cancer, Lipid and atherosclerosis D03106 Bexarotene 2件: 13, 75
611 SCN1A 1件: Dopaminergic synapse D00252 Carbamazepine 2件: 13, 231
612 SCN1A 1件: Dopaminergic synapse D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
613 SCN1A 1件: Dopaminergic synapse D00358 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
614 SCN1A 1件: Dopaminergic synapse D00512 Phenytoin 1件: 13
615 SCN1A 1件: Dopaminergic synapse D00533 Oxcarbazepine 1件: 13
616 SCN1A 1件: Dopaminergic synapse D00642 Quinidine 1件: 13
617 SCN1A 1件: Dopaminergic synapse D00643 Quinidine 1件: 13
618 SCN1A 1件: Dopaminergic synapse D02086 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
619 SCN1A 1件: Dopaminergic synapse D02103 Phenytoin 1件: 13
620 SCN1A 1件: Dopaminergic synapse D02272 Quinidine 1件: 13
621 SCN1A 1件: Dopaminergic synapse D08127 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
622 SCN1A 1件: Dopaminergic synapse D08458 Quinidine 1件: 13
623 SCN2A 1件: Taste transduction D00252 Carbamazepine 2件: 13, 231
624 SCN2A 1件: Taste transduction D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
625 SCN2A 1件: Taste transduction D00358 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
626 SCN2A 1件: Taste transduction D00512 Phenytoin 1件: 13
627 SCN2A 1件: Taste transduction D00533 Oxcarbazepine 1件: 13
628 SCN2A 1件: Taste transduction D00642 Quinidine 1件: 13
629 SCN2A 1件: Taste transduction D00643 Quinidine 1件: 13
630 SCN2A 1件: Taste transduction D02086 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
631 SCN2A 1件: Taste transduction D02103 Phenytoin 1件: 13
632 SCN2A 1件: Taste transduction D02272 Quinidine 1件: 13
633 SCN2A 1件: Taste transduction D08127 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
634 SCN2A 1件: Taste transduction D08458 Quinidine 1件: 13
635 SCN3A 1件: Taste transduction D00252 Carbamazepine 2件: 13, 231
636 SCN3A 1件: Taste transduction D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
637 SCN3A 1件: Taste transduction D00358 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
638 SCN3A 1件: Taste transduction D00512 Phenytoin 1件: 13
639 SCN3A 1件: Taste transduction D00533 Oxcarbazepine 1件: 13
640 SCN3A 1件: Taste transduction D00642 Quinidine 1件: 13
641 SCN3A 1件: Taste transduction D00643 Quinidine 1件: 13
642 SCN3A 1件: Taste transduction D02086 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
643 SCN3A 1件: Taste transduction D02103 Phenytoin 1件: 13
644 SCN3A 1件: Taste transduction D02272 Quinidine 1件: 13
645 SCN3A 1件: Taste transduction D08127 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
646 SCN3A 1件: Taste transduction D08458 Quinidine 1件: 13
647 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00252 Carbamazepine 2件: 13, 231
648 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
649 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00358 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
650 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00512 Phenytoin 1件: 13
651 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00533 Oxcarbazepine 1件: 13
652 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00642 Quinidine 1件: 13
653 SCN5A 1件: Adrenergic signaling in cardiomyocytes D00643 Quinidine 1件: 13
654 SCN5A 1件: Adrenergic signaling in cardiomyocytes D02086 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
655 SCN5A 1件: Adrenergic signaling in cardiomyocytes D02103 Phenytoin 1件: 13
656 SCN5A 1件: Adrenergic signaling in cardiomyocytes D02272 Quinidine 1件: 13
657 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08127 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
658 SCN5A 1件: Adrenergic signaling in cardiomyocytes D08458 Quinidine 1件: 13
659 SCN9A 1件: Taste transduction D00252 Carbamazepine 2件: 13, 231
660 SCN9A 1件: Taste transduction D00354 Lamotrigine 5件: 13, 34, 38, 114, 144
661 SCN9A 1件: Taste transduction D00358 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
662 SCN9A 1件: Taste transduction D00512 Phenytoin 1件: 13
663 SCN9A 1件: Taste transduction D00533 Oxcarbazepine 1件: 13
664 SCN9A 1件: Taste transduction D00642 Quinidine 1件: 13
665 SCN9A 1件: Taste transduction D00643 Quinidine 1件: 13
666 SCN9A 1件: Taste transduction D02086 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
667 SCN9A 1件: Taste transduction D02103 Phenytoin 1件: 13
668 SCN9A 1件: Taste transduction D02272 Quinidine 1件: 13
669 SCN9A 1件: Taste transduction D08127 Lidocaine 12件: 13, 34, 46, 51, 70, 84, 86, 107, 168, 226, 231, 256
670 SCN9A 1件: Taste transduction D08458 Quinidine 1件: 13
671 SCNN1A 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D00649 Amiloride 4件: 13, 67, 225, 299
672 SCNN1A 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D07447 Amiloride 4件: 13, 67, 225, 299
673 SCNN1B 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D00649 Amiloride 4件: 13, 67, 225, 299
674 SCNN1B 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D07447 Amiloride 4件: 13, 67, 225, 299
675 SCNN1G 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D00649 Amiloride 4件: 13, 67, 225, 299
676 SCNN1G 2件: Taste transduction, Aldosterone-regulated sodium reabsorption D07447 Amiloride 4件: 13, 67, 225, 299
677 CCL2 17件: Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, Chemokine signaling pathway, NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Yersinia infection, Chagas disease, Malaria, Human cytomegalovirus infection, Influenza A, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Rheumatoid arthritis, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
678 SLC6A1 2件: Synaptic vesicle cycle, GABAergic synapse D00332 Gabapentin 5件: 6, 13, 19, 70, 298
679 SLC6A2 1件: Synaptic vesicle cycle D00821 Venlafaxine 2件: 13, 46
680 SLC6A2 1件: Synaptic vesicle cycle D01179 Duloxetine 1件: 13
681 SLC6A2 1件: Synaptic vesicle cycle D01296 Methylphenidate 6件: 13, 34, 84, 113, 179, 206
682 SLC6A2 1件: Synaptic vesicle cycle D02574 Atomoxetine 2件: 13, 17
683 SLC6A2 1件: Synaptic vesicle cycle D04999 Methylphenidate 6件: 13, 34, 84, 113, 179, 206
684 SLC6A2 1件: Synaptic vesicle cycle D07473 Atomoxetine 2件: 13, 17
685 SLC6A2 1件: Synaptic vesicle cycle D07880 Duloxetine 1件: 13
686 SLC6A2 1件: Synaptic vesicle cycle D08130 Lisdexamfetamine 1件: 13
687 SLC6A2 1件: Synaptic vesicle cycle D08670 Venlafaxine 2件: 13, 46
688 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D01296 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
689 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D03215 Armodafinil 3件: 6, 13, 84
690 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D04999 Methylphenidate 7件: 6, 13, 34, 84, 113, 179, 206
691 SLC6A3 7件: Synaptic vesicle cycle, Dopaminergic synapse, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Cocaine addiction, Amphetamine addiction, Alcoholism D08130 Lisdexamfetamine 1件: 13
692 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00326 Fluoxetine 6件: 13, 17, 78, 86, 179, 206
693 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00821 Venlafaxine 3件: 6, 13, 46
694 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00822 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
695 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D00823 Fluoxetine 6件: 13, 17, 78, 86, 179, 206
696 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D01179 Duloxetine 2件: 6, 13
697 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02260 Paroxetine 4件: 6, 13, 46, 85
698 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02362 Paroxetine 4件: 6, 13, 46, 85
699 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D02567 Escitalopram 3件: 2, 6, 13
700 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D05374 Paroxetine 4件: 6, 13, 46, 85
701 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D05375 Paroxetine 4件: 6, 13, 46, 85
702 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07704 Citalopram 7件: 6, 8, 13, 18, 46, 98, 127
703 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07704 Escitalopram 3件: 2, 6, 13
704 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07880 Duloxetine 2件: 6, 13
705 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D07913 Escitalopram 3件: 2, 6, 13
706 SLC6A4 2件: Synaptic vesicle cycle, Serotonergic synapse D08670 Venlafaxine 3件: 6, 13, 46
707 SLC12A3 - D00340 Hydrochlorothiazide 4件: 13, 67, 225, 235
708 SLC12A3 - D00345 Indapamide 1件: 13
709 SLC12A3 - D06401 Indapamide 1件: 13
710 SNAP25 2件: Synaptic vesicle cycle, Insulin secretion D00783 Botulinum toxin type A 13件: 2, 5, 6, 7, 13, 15, 17, 36, 51, 70, 113, 149, 226
711 SNAP25 2件: Synaptic vesicle cycle, Insulin secretion D02735 Botulinum toxin type B 4件: 2, 6, 13, 51
712 ABCC8 3件: ABC transporters, Insulin secretion, Type II diabetes mellitus D00294 Diazoxide 2件: 13, 193
713 TBXA2R 3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation D01128 Ramatroban 1件: 13
714 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11457 Fenebrutinib 1件: 13
715 BTK 7件: NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, B cell receptor signaling pathway, Fc epsilon RI signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D12160 Orelabrutinib 3件: 13, 61, 63
716 THRA 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D01011 Liothyronine 4件: 13, 78, 210, 212
717 THRA 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine 4件: 13, 78, 210, 212
718 THRB 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D01011 Liothyronine 4件: 13, 78, 210, 212
719 THRB 2件: Neuroactive ligand-receptor interaction, Thyroid hormone signaling pathway D08128 Liothyronine 4件: 13, 78, 210, 212
720 TNF 67件: Antifolate resistance, MAPK signaling pathway, Cytokine-cytokine receptor interaction, Viral protein interaction with cytokine and cytokine receptor, NF-kappa B signaling pathway, Sphingolipid signaling pathway, mTOR signaling pathway, Apoptosis, Necroptosis, TGF-beta signaling pathway, Osteoclast differentiation, Antigen processing and presentation, Toll-like receptor signaling pathway, NOD-like receptor signaling pathway, RIG-I-like receptor signaling pathway, C-type lectin receptor signaling pathway, Hematopoietic cell lineage, Natural killer cell mediated cytotoxicity, IL-17 signaling pathway, T cell receptor signaling pathway, Fc epsilon RI signaling pathway, TNF signaling pathway, Adipocytokine signaling pathway, Type II diabetes mellitus, Insulin resistance, Non-alcoholic fatty liver disease, AGE-RAGE signaling pathway in diabetic complications, Alcoholic liver disease, Type I diabetes mellitus, Alzheimer disease, Amyotrophic lateral sclerosis, Prion disease, Pathways of neurodegeneration - multiple diseases, Pathogenic Escherichia coli infection, Shigellosis, Salmonella infection, Pertussis, Legionellosis, Yersinia infection, Leishmaniasis, Chagas disease, African trypanosomiasis, Malaria, Toxoplasmosis, Amoebiasis, Tuberculosis, Hepatitis C, Hepatitis B, Human cytomegalovirus infection, Influenza A, Human papillomavirus infection, Human T-cell leukemia virus 1 infection, Herpes simplex virus 1 infection, Epstein-Barr virus infection, Human immunodeficiency virus 1 infection, Coronavirus disease - COVID-19, Proteoglycans in cancer, Asthma, Inflammatory bowel disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Hypertrophic cardiomyopathy, Dilated cardiomyopathy, Lipid and atherosclerosis, Fluid shear stress and atherosclerosis D01583 Pirfenidone 11件: 13, 34, 46, 50, 51, 58, 84, 85, 164, 222, 228
721 TOP2A 1件: Platinum drug resistance D00125 Etoposide 10件: 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
722 TOP2A 1件: Platinum drug resistance D02166 Mitoxantrone 1件: 13
723 TOP2A 1件: Platinum drug resistance D03730 Dexrazoxane 1件: 13
724 TOP2A 1件: Platinum drug resistance D04107 Etoposide 10件: 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
725 TOP2A 1件: Platinum drug resistance D05522 Pixantrone 1件: 13
726 TOP2A 1件: Platinum drug resistance D08224 Mitoxantrone 1件: 13
727 TOP2B 1件: Platinum drug resistance D00125 Etoposide 10件: 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
728 TOP2B 1件: Platinum drug resistance D02166 Mitoxantrone 1件: 13
729 TOP2B 1件: Platinum drug resistance D03730 Dexrazoxane 1件: 13
730 TOP2B 1件: Platinum drug resistance D04107 Etoposide 10件: 13, 14, 26, 28, 34, 60, 65, 85, 164, 331
731 TOP2B 1件: Platinum drug resistance D05522 Pixantrone 1件: 13
732 TOP2B 1件: Platinum drug resistance D08224 Mitoxantrone 1件: 13
733 C5 10件: Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus D03940 Eculizumab 7件: 11, 13, 14, 61, 62, 109, 222
734 C5 10件: Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Neutrophil extracellular trap formation, Alcoholic liver disease, Prion disease, Pertussis, Staphylococcus aureus infection, Herpes simplex virus 1 infection, Coronavirus disease - COVID-19, Systemic lupus erythematosus D11054 Ravulizumab 7件: 2, 11, 13, 50, 62, 66, 109
735 VDR 5件: Parathyroid hormone synthesis, secretion and action, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Tuberculosis, Chemical carcinogenesis - receptor activation D00188 Cholecalciferol 25件: 6, 13, 19, 20, 28, 34, 46, 49, 51, 53, 56, 60, 65, 75, 84, 85, 96, 97, 98, 162, 202, 228, 271, 298, 299
736 VEGFA 24件: EGFR tyrosine kinase inhibitor resistance, MAPK signaling pathway, Ras signaling pathway, Rap1 signaling pathway, Calcium signaling pathway, HIF-1 signaling pathway, PI3K-Akt signaling pathway, VEGF signaling pathway, Focal adhesion, Relaxin signaling pathway, AGE-RAGE signaling pathway in diabetic complications, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, Pathways in cancer, Proteoglycans in cancer, MicroRNAs in cancer, Chemical carcinogenesis - receptor activation, Chemical carcinogenesis - reactive oxygen species, Renal cell carcinoma, Pancreatic cancer, Bladder cancer, Rheumatoid arthritis, Fluid shear stress and atherosclerosis D06409 Bevacizumab 9件: 13, 34, 85, 86, 87, 89, 227, 280, 331
737 XDH 5件: Purine metabolism, Caffeine metabolism, Drug metabolism - other enzymes, Metabolic pathways, Peroxisome D01206 Febuxostat 3件: 2, 6, 13
738 CA1 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
739 CA1 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
740 CA2 7件: Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
741 CA2 7件: Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation, Collecting duct acid secretion, Gastric acid secretion, Pancreatic secretion, Bile secretion D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
742 CA3 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
743 CA3 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
744 CA4 3件: Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
745 CA4 3件: Nitrogen metabolism, Metabolic pathways, Proximal tubule bicarbonate reclamation D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
746 CA5A 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
747 CA5A 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
748 CA6 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
749 CA6 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
750 CA7 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
751 CA7 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
752 CA8 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
753 CA8 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
754 CA9 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
755 CA9 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
756 CA12 2件: Nitrogen metabolism, Metabolic pathways D00218 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
757 CA12 2件: Nitrogen metabolism, Metabolic pathways D01196 Acetazolamide 8件: 13, 86, 90, 115, 154, 155, 225, 230
758 CACNA1C 34件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
759 CACNA1C 34件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
760 CACNA1C 34件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Circadian entrainment, Long-term potentiation, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Taste transduction, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
761 CACNA1D 35件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
762 CACNA1D 35件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
763 CACNA1D 35件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cellular senescence, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Tight junction, Circadian entrainment, Retrograde endocannabinoid signaling, Glutamatergic synapse, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Dopaminergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome, Growth hormone synthesis, secretion and action, Carbohydrate digestion and absorption, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Amphetamine addiction, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
764 CACNA1F 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
765 CACNA1F 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
766 CACNA1F 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
767 CACNA1S 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00615 Amlodipine 4件: 13, 51, 67, 298
768 CACNA1S 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02914 Amlodipine 4件: 13, 51, 67, 298
769 CACNA1S 27件: MAPK signaling pathway, Calcium signaling pathway, cGMP-PKG signaling pathway, cAMP signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Vascular smooth muscle contraction, Retrograde endocannabinoid signaling, Cholinergic synapse, Serotonergic synapse, GABAergic synapse, Insulin secretion, GnRH signaling pathway, Oxytocin signaling pathway, Renin secretion, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome, Growth hormone synthesis, secretion and action, Alzheimer disease, Prion disease, Pathways of neurodegeneration - multiple diseases, Chemical carcinogenesis - receptor activation, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D07450 Amlodipine 4件: 13, 51, 67, 298
770 CACNA2D1 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
771 CACNA2D1 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
772 IL1R2 7件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Amoebiasis, Human T-cell leukemia virus 1 infection, Transcriptional misregulation in cancer, Prostate cancer, Fluid shear stress and atherosclerosis D02934 Anakinra 19件: 2, 13, 15, 19, 28, 37, 41, 46, 49, 50, 56, 65, 84, 86, 97, 106, 107, 266, 299
773 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D00564 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
774 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D01280 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
775 VKORC1 3件: Ubiquinone and other terpenoid-quinone biosynthesis, Metabolic pathways, Biosynthesis of cofactors D08682 Warfarin 13件: 6, 8, 13, 19, 46, 49, 66, 85, 86, 88, 91, 96, 97
776 ALDH5A1 3件: Alanine, aspartate and glutamate metabolism, Butanoate metabolism, Metabolic pathways D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
777 TAS1R2 2件: Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame 5件: 6, 13, 67, 86, 230
778 TAS1R3 2件: Taste transduction, Carbohydrate digestion and absorption D02381 Aspartame 5件: 6, 13, 67, 86, 230
779 LINGO1 - D11767 Opicinumab 1件: 13
780 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D00528 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
781 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D01453 Caffeine 9件: 2, 6, 13, 21, 46, 78, 96, 97, 265
782 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D02731 Vardenafil 3件: 13, 86, 299
783 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D03260 Vardenafil 3件: 13, 86, 299
784 PDE5A 3件: Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway D08668 Vardenafil 3件: 13, 86, 299
785 S1PR4 3件: FoxO signaling pathway, Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
786 TNFSF13 3件: Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, Rheumatoid arthritis D09704 Atacicept 4件: 13, 46, 49, 66
787 CACNA1I 7件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
788 CACNA1H 7件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Cushing syndrome D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
789 CACNA1G 8件: MAPK signaling pathway, Calcium signaling pathway, Circadian entrainment, Aldosterone synthesis and secretion, Cortisol synthesis and secretion, GnRH secretion, Type II diabetes mellitus, Cushing syndrome D00399 Valproic acid 17件: 2, 3, 5, 6, 13, 26, 34, 65, 85, 89, 90, 102, 127, 222, 233, 256, 331
790 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D03365 Nicotine 3件: 6, 13, 84
791 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05156 Nicotine 3件: 6, 13, 84
792 CHRNA6 3件: Neuroactive ligand-receptor interaction, Cholinergic synapse, Nicotine addiction D05157 Nicotine 3件: 6, 13, 84
793 CACNA2D2 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
794 CACNA2D2 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
795 S1PR2 2件: Sphingolipid signaling pathway, Neuroactive ligand-receptor interaction D10968 Ozanimod 3件: 13, 96, 97
796 CD19 5件: PI3K-Akt signaling pathway, Hematopoietic cell lineage, B cell receptor signaling pathway, Epstein-Barr virus infection, Primary immunodeficiency D11757 Inebilizumab 4件: 11, 13, 51, 300
797 MS4A1 1件: Hematopoietic cell lineage D02994 Rituximab 47件: 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331
798 MS4A1 1件: Hematopoietic cell lineage D05218 Ocrelizumab 3件: 13, 46, 49
799 MS4A1 1件: Hematopoietic cell lineage D09314 Ofatumumab 3件: 13, 35, 46
800 MS4A1 1件: Hematopoietic cell lineage D11243 Ublituximab 1件: 13
801 CACNA2D4 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D00332 Gabapentin 5件: 6, 13, 19, 70, 298
802 CACNA2D4 7件: MAPK signaling pathway, Cardiac muscle contraction, Adrenergic signaling in cardiomyocytes, Oxytocin signaling pathway, Hypertrophic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy D02716 Pregabalin 5件: 13, 36, 46, 70, 298
803 CD80 10件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
804 CD86 12件: Cell adhesion molecules, Toll-like receptor signaling pathway, Intestinal immune network for IgA production, Type I diabetes mellitus, Kaposi sarcoma-associated herpesvirus infection, Transcriptional misregulation in cancer, Autoimmune thyroid disease, Systemic lupus erythematosus, Rheumatoid arthritis, Allograft rejection, Graft-versus-host disease, Viral myocarditis D03203 Abatacept 26件: 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300
805 GABBR2 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D00241 Baclofen 7件: 2, 10, 13, 18, 65, 149, 206
806 GABBR2 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D08861 Arbaclofen Placarbil 1件: 13
807 GABBR2 7件: cAMP signaling pathway, Neuroactive ligand-receptor interaction, GABAergic synapse, Taste transduction, Estrogen signaling pathway, GnRH secretion, Morphine addiction D09791 Arbaclofen 2件: 13, 206
808 KEAP1 6件: Ubiquitin mediated proteolysis, Parkinson disease, Pathways in cancer, Chemical carcinogenesis - reactive oxygen species, Hepatocellular carcinoma, Fluid shear stress and atherosclerosis D03846 Dimethyl fumarate 5件: 13, 49, 51, 86, 296
809 SV2A 1件: ECM-receptor interaction D00709 Levetiracetam 2件: 13, 307